A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia

Inclusion Criteria:

* Age \>= 18 years.
* Must have received prior therapy for their WM and have relapsed or refractory WM. Any number of prior therapies is acceptable.
* Measurable disease, defined as presence of immunoglobulin M (IgM) paraprotein with a minimum IgM level of \> 2 times the upper limit of each institution's normal value is required and over 10% of lymphoplasmacytic cells in the bone marrow.
* ECOG Performance Status (PS) 0, 1, or 2.
* The following laboratory values obtained 14 days prior to registration
* ANC \>= 1 x109/L
* PLT \>= 75 x109/L
* Total bilirubin ≤ 2.0 mg/dL (If total is elevated check direct and if normal patient is eligible.)
* AST \<= 3 x upper limit of normal (ULN)
* Creatinine \<= 2 x ULN
* Ability to provide informed consent.
* Life expectancy \>= 12 weeks.

Exclusion Criteria:

* Uncontrolled infection.
* Other active malignancies.
* CNS involvement.
* Cytotoxic chemotherapy ≤ 3 weeks, or biologic therapy ≤ 2 weeks, or corticosteroids ≤ 2 weeks, prior to registration. Patients may be receiving chronic corticosteroids if they are being given for disorders other than WM such as auto-immune diseases. Plasmapheresis is not considered as an active therapy and can be used at the physician's discretion.
* Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational.
* Any of the following:
* Pregnant women
* Nursing women
* Men or women of childbearing potential who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device (IUD), or abstinence, etc.)
* Known to be HIV positive.
* Radiation therapy ≤ 2 weeks prior to registration.